Prognostic value of IGFBP7 in solid tumors: a meta analysis of 1,305 patients

Borong Chen
the first affiliated hospital of Xiamen University

Heqing Huang
the first affiliated hospital of xiamen university

Jiuhua Xu
fujian medical university

Lulu Li
the first affiliated hospital of xiamen university

Weipeng Ye
fujian medical university

Zhipeng Zhu
the first affiliated hospital of xiamen university

Junjie Zeng
the first affiliated hospital of xiamen university

Jiayi Li
the first affiliated hospital of xiamen university

Zhengjie Huang  huangzhengjie@xmu.edu.cn
First Affiliated Hospital of Xiamen University
Corresponding Author

DOI: 10.21203/rs.2.13241/v1

SUBJECT AREAS Oncology

KEYWORDS IGFBP7, prognosis, meta-analysis
Abstract

Background: Insulin-like growth factor-binding protein 7 (IGFBP7) has been detected to act as a cancer suppressor gene in different types of human carcinoma. Previous studies have presented controversial evidences between the expression of IGFBP7 and prognosis in solid tumors. A comprehensive meta-analysis was performed to investigate the prognostic role of IGFBP7 expression.

Methods: The studies were identified through extensive electronic search of Web of Science, PubMed and Embase up to Jun 2019. The pooled hazard ratios (HR) with corresponding 95% confidence intervals (CI) for overall survival (OS) were calculated through univariate analysis and multivariate analysis to investigate the prognostic value of IGFBP7 expression. Heterogeneity, publication bias and subgroup analyses were also performed.

Results: Seven eligible studies including 1,305 patients were extracted in this analysis. The pooled hazard ratio of univariable analysis for OS (HR = 0.60; 95% CI, 0.54–0.66, P < 0.001). The pooled hazard ratio of multivariate analysis for OS (HR = 0.57; 95% CI, 0.50–0.64, P < 0.001). In addition, subgroup analysis showed that low IGFBP7 expression was significantly associated with poor prognosis in patients with digestive system cancer.

Conclusions: Low-expression of IGFBP7 was correlated strongly with worse OS, which indicated that IGFBP7 might be a new biomarker for prognosis prediction and a promising therapeutic target in solid tumors. Keywords: IGFBP7, prognosis, meta-analysis

Background
Insulin-like growth factor-binding protein 7 (IGFBP7) also called as IGFB-related protein 1 or mac25, which is a secreted protein belongs to the IGFBPs family.[1, 2] IGFBP7 has been detected in various normal human tissues including brain, heart and kidney.[3] Functionally, IGFBP7 play central roles in the process of cellular senescence and apoptosis. Wajapeyee et al.[4] demonstrated that IGFBP7 through inhibit BRAF-MEK-ERK signaling pathways to induce cellular senescence and apoptosis. Subsequently, Severino et al.[5] reported that IGFBP7 could induce senescence in mesenchymal stromal cells. In vitro studies shown that IGFBP7 might inhibit cancer cells proliferation via a senescence-like mechanism.[6] Indeed, IGFBP7 was well known for its function as a growth-suppressing factor.[7] Precious study suggested that IGFBP7 could markedly suppressed growth of BRAFV600E - positive tumors in xenografted mice.[4] Suzuki et al.[8] indicated that IGFBP7 is a direct region of p53-dependent growth inhibition in colorectal cancer. Further researches reported that IGFBP7 could through suppress the phosphorylation of the mitogen-activated protein kinases ERK–1/2 to mediate the growth of breast cancer cells.[9] In addition, IGFBP7 via delaying the cells in the G1 phase of the cell cycle to suppress prostate cancer cells growth.[2] Consistently, the tumor suppressor role of IGFBP7 has been identified in lung cancer,[10] thyroid tumour,[11] hepatocellular carcinoma.[12]

There is increasing evidence showing that IGFBP7 downregulation was significantly associated with unfavorable clinical outcome in several types of human malignant tumors, including two gastric cancer,[13, 14] cholangiocarcinoma,[15] human glioma,[16] pancreatic ductal adenocarcinoma,[17] hepatocellular carcinoma,[18] and colorectal cancer.[19] However, previous studies have presented controversial evidences between the expression of IGFBP7 and prognosis in solid
tumors. Therefore, we conducted this comprehensive meta-analysis to summarize the clinical role of IGFBP7 expression with overall survival (OS) for cancer patients.

Methods

Literature search and selection criteria

In order to obtaining latent eligible studies, an electronic literature retrieval was undertaken for articles about IGFBP7 expression and clinical prognosis in Web of Science, PubMed and Embase until Jun 2019. The keywords for searching terms including: “Insulin-like growth factor-binding protein 7” or “IGFBP7” “IGFBP-rP1” or “mac25” and “cancer” or “tumor” or “neoplasm” or “carcinoma,” and “prognosis” or “survival”. Only the human studies of solid tumor were selected. Totally 1436 articles were retrieved.

The eligible articles must to meet all the following inclusion criteria: the association between IGFBP7 expression and OS were investigated in solid tumor, the hazard ratios (HR) and corresponding 95% confidence intervals (CI) could obtained or estimated by the published data, and the original studies must be a English language publication. Excluded refer to the following criteria: overlapped data or duplicate studies, studies were book, letter, conference abstract or reviews, studies about basic research or animal experiments which did not reported available data. Two investigators (HH and XJ) independently evaluated the eligible articles, any divergences were resolved by discussion with a third assessor (CB).

Data extraction and quality assessment

Two independent investigators (XJ and LL) carefully extracted the data and clinical information from each eligible publication: author’s name, year of published, original country, tumor type, number of patients, gender, median age, detection
means, cut-off value of IGFBP7, follow-up time, OS, and NOS scores. The HR and 95% CI were extracted from the original data or Kaplan-Meier curves. The Newcastle-Ottawa Scale (NOS) [20] was performed to detect the quality of each eligible articles. Only NOS score ≥ 6 was considered as high quality publication.

**Statistical analysis**

HR and 95% CI were obtained from the included articles or extracted through Kaplan-Meier method according to Tierney’s method.[21] Next, those data were analyzed by RevMan 5.3 analysis software (Cochrane Collaboration, Copenhagen, Denmark). Statistical heterogeneity was evaluated using Higgins’ I² statistics and Cochran’s Q test.[22, 23] Fixed-effects model (Mantel-Haenszel) was performed when I² < 50% and P > 0.05. In addition, random-effects model (DerSimonian and Laird) was conducted when I²≥ 50% and P≤ 0.05. Besides, Subgroup analysis was applied to detect the heterogeneity source. Begg’s funnel plot and Egger’s test also conducted to evaluate the publication bias risk though STATA 12.0 software. The statistical significance was considered as P < 0.05.

**Results**

**Study characteristics**

A flow diagram about the article selection process were shown (Figure 1).

Firstly, there are 1436 potential articles were retrieved in Web of Science, PubMed and Embase. According to the inclusion criteria described above, finally, 7 eligible publications were identified in the present study. The general characteristic of 7 eligible articles were shown in Table 1. Totally, 1305 solid tumor patients were included, which refer to three countries (People’s Republic of China, Japan, Korea). In addition, this study analyzed six types of solid tumors: two gastric cancer, [13,
cholangiocarcinoma, [15] human glioma, [16] pancreatic ductal adenocarcinoma, [17] hepatocellular carcinoma, [18] and colorectal cancer. [19] OS rate is a crucial indicator for clinical observation of cancer prognosis. Thus, this study was conducted to analyze OS. Furthermore, all involved studies got more than 6 quality score in NOS assessment (Table 2).

**Overall survival (univariate analysis)**

The comprehensive analysis of 6 univariate analysis published data indicated that low IGFBP7 expression was associated with worse OS of solid tumors (HR = 0.60; 95% CI, 0.54–0.66, \( P < 0.001 \)). It reported no significant heterogeneity (\( I^2 = 44\% \), \( P = 0.11 \)), so we use a fixed-effects model (Figure 2). Then, a subgroup analysis was conducted to analysis by cancer type, which indicated a negative outcome of low IGFBP7 expression on OS in patients with digestive system cancer (HR = 0.60; 95% CI, 0.53–0.66, \( P < 0.001 \)) (Figure 3A), and other system cancer (HR = 0.61; 95% CI, 0.39–0.95, \( P = 0.03 \)) (Figure 3B). Consistently, the subgroup analysis by country revealed an association between IGFBP7 downregulation and unfavorable prognosis on OS in Chinese patient with soild tumors (HR = 0.57; 95% CI, 0.43–0.74, \( P < 0.001 \)) (Figure 3C), and other country (HR = 0.55; 95% CI, 0.38–0.80, \( P = 0.002 \)) (Figure 3D). Besides, all of the pooled HR are shown in Table 3.

**Overall survival (multivariate analysis)**

The pooled analysis of 6 multivariate analysis results demonstrated that IGFBP7 downregulation was associated with worse survival outcome in solid tumor patients (HR = 0.57; 95% CI, 0.50–0.64, \( P < 0.001 \)). It suggested no significant heterogeneity (\( I^2 = 1\% \), \( P = 0.41 \)), so we perform a fixed-effects model (Figure 4). In addition, a subgroup analysis was conducted to analysis by cancer type, which suggested low-level expression of IGFBP7 was correlated strongly with poor OS in patients with
digestive system cancer (HR = 0.56; 95% CI, 0.49–0.64, \( P < 0.001 \)) (Figure 5A), and other system cancer (HR = 0.62; 95% CI, 0.40–0.96, \( P = 0.03 \)) (Figure 5B).

Similarity, the subgroup analysis by country indicated a negative outcome of low IGFBP7 expression on OS in Chinese patient with solid tumors (HR = 0.57; 95% CI, 0.50–0.65, \( P < 0.001 \)) (Figure 5C), and other country (HR = 0.55; 95% CI, 0.39–0.77, \( P < 0.001 \)) (Figure 5D).

Publication bias

In this meta-analysis, the potential publication bias was evaluated through Begg’s funnel plot and Egger’s test. The results for univariate analysis (\( P = 0.261 \)) (Figure 6A) and multivariate analysis (\( P = 0.791 \)) (Figure 6B) showed that significant publication bias did not exist.

Discussion

Human solid tumor as the most common malignant cancer leading a high cancer-related deaths in worldwide.[24, 25] Therefore, to identifying effective biomarkers for the prognostic prediction and therapeutic target of human solid tumors are clearly needed.

Previous studies have indicated that insulin-like growth factor (IGF) signaling pathway is a finely tuned network formed by IGFs, their receptors and IGFBPs, which play a crucial role in regulating cancer cells proliferation, differentiation and apoptosis.[26] IGFBP7 have been reported to be involved in both IGF-dependent and IGF-independent pathways.[1, 27] Heesch et al.[28] demonstrated that aberrant IGFBP7 expression was correlated with DNA methylation in acute leukemia. Consistently, the absence of IGFBP7 expression in colon cancer was associated with its methylation.[29] Interestingly, DNA methylation play a important role in clinical
detected, which may lead to biomarkers for early detection, prognosis and therapeutic monitoring. Moreover, a published study suggested that downregulate the expression of IGFBP7 was significant correlation with chemotherapeutic drug resistance in hepatocellular carcinoma.[30] Subsequently, Okamura et al.[31] indicated that the transcriptional level of IGFBP7 was reduced in cisplatin-resistant human non-small cell lung cancer cells and knock-down of IGFBP7 increased cellular resistance to cisplatin. Verhagen et al.[32] suggested that increase expression of IGFBP7 results in enhanced sensitivity to chemotherapy-induced cell death in acute myeloid leukemia. Additionally, in several cancers mouse models treat with recombinant IGFBP7 shown effective cancer inhibition.[33, 34] Taken together, it seems noteworthy that IGFBP7 might be a novel therapeutic target in human solid tumors.

Accumulating research reported that the expression level of IGFBP7 has a crucial impact on clinical outcome. It has been shown that IGFBP7 play a negative effect on the growth of cancer cells and high expression of IGFBP7 correlated with favorable prognosis in colorectal cancer.[19] Tomimaru et al.[18] demonstrated that downregulation of IGFBP7 was significantly associated with both tumor progression and poor OS in hepatocellular carcinoma. Furthermore, in gastric cancer patients, silenced of IGFBP7 markedly correlated with worse clinical prognosis.[13] These evidences indicate that IGFBP7 play a key role in tumor microenvironment and significantly associated with clinical prognosis in cancer patients. Therefore, we aim to investigate the prognostic role of IGFBP7 in patients with solid tumor through this comprehensive meta-analysis.

In this analysis, we comprehensively evaluated the survival data of 1305 solid tumor patients. These meta-analysis results suggest that low-expression of IGFBP7
was statistically significant associated with worse OS both in multivariate analysis and univariate analysis. As for subgroup analysis, the results showed that downregulation of IGFBP7 was also strongly correlated with poor OS in digestive system cancers and human glioma. These evidences highlight the potential role of IGFBP7 to be a crucial prognostic marker and therapeutic target for solid tumors. However, the clinical feature and therapeutic outcome of IGFBP7 need to further confirmed.

There are several limitations may exist in this meta-analysis. On one hand, some publication bias and selection bias are unavoidable because of only English language published articles were selected. On the other hand, it was inconsistent in the method for detection of IGFBP7 expression. In addition, there are some data were indirectly extracted from Kaplan–Meier curves. More multicenter prospective studies are required to further confirm the prognostic and clinicopathological significances of IGFBP7 expression in human solid tumors.

Conclusions
In conclusion, low-expression of IGFBP7 was correlated strongly with worse OS, which indicated that IGFBP7 might be a new biomarker for prognosis prediction and a promising therapeutic target in solid tumors.

Declarations

List of abbreviations
CI = confidence interval, HR = hazard ratio, IGF = insulin-like growth factor, IGFBP7 = insulin-like growth factor binding protein 7, IGFBP-rP1 = insulin-like growth factor binding protein-related protein–1, IHC = immunohistochemistry, IV = inverse
variance, M = multivariate analysis, No = number, NOS = Newcastle-Ottawa, NR = not reported, OS = overall survival, SE = standard error, U = univariate analysis.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Availability of data and material
The datasets used in the present study are available from the corresponding author upon reasonable request.

Competing interests
Not competing interests.

Funding
The write and design of this study were supported by grants from the Medical Innovations Topic in Fujian Province (no.2016-CXB-8). Collection and analysis of these data were supported by Project of Xiamen Scientific and Technological Plan (no. 3502Z20184020).

Authors contributors
CB and HZ designed and performed the study. HH and XJ carried out the literature selection criteria and developed the literature search. XJ and LL extracted the original data. YW, ZZ and LJ performed the statistical analysis. ZJ and HH processed related figures and tables. CB and HZ drafted the manuscript. All authors read and approved this final manuscript.

Acknowledgements
The authors would like to thank the researchers of the primary studies.

Author details
1 Department of Gastrointestinal Surgery, Xiamen Cancer Hospital of The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China. 2 Department of General Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China. 3 Department of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian, China. 4 Department of Medical Oncology, Xiamen Cancer Hospital of The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.

References

1. Hwa, V., Y. Oh, and R. G. Rosenfeld, The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocrine Reviews, 1999. 20(6): p. 761–787.

2. Sprenger, C. C., et al., Over-expression of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene, 2002. 21(1): p. 140–147.

3. Degeorges, A., et al., Distribution of IGFBP-rP1 in normal human tissues. Journal of Histochemistry & Cytochemistry, 2000. 48(6): p. 747–754.

4. Wajapeyee, N., et al., Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell, 2008. 132(3): p. 363–374.

5. Severino, V., et al., Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells. Cell Death & Disease, 2013. 4.

6. Wilson, H. M. P., et al., Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth & Differentiation, 2002. 13(5): p. 205–213.
7. Oh, Y. M., et al., *Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7 - Recombinant human mac25 protein specifically binds IGF-I and II*. Journal of Biological Chemistry, 1996. 271(48): p. 30322-30325.

8. Suzuki, H., et al., *IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype*. Carcinogenesis, 2010. 31(3): p. 342-349.

9. Amemiya, Y., et al., *Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors*. Breast Cancer Research and Treatment, 2011. 126(2): p. 373-384.

10. Chen, Y., et al., *Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer*. J Pathol, 2007. 211(4): p. 431-8.

11. Vizioli, M. G., et al., *IGFBP7: an oncosuppressor gene in thyroid carcinogenesis*. Oncogene, 2010. 29(26): p. 3835-44.

12. Chen, D., et al., *Insulin-like Growth Factor-binding Protein-7 (IGFBP7): A Promising Gene Therapeutic for Hepatocellular Carcinoma (HCC)*. Molecular Therapy, 2013. 21(4): p. 758-766.

13. Kim, J., et al., *Epigenetic Downregulation and Growth Inhibition of IGFBP7 in Gastric Cancer*. Asian Pac J Cancer Prev, 2018. 19(3): p. 667-675.

14. Liu, L., et al., *Decreased expression of IGFBP7 was a poor prognosis predictor for gastric cancer patients*. Tumor Biology, 2014. 35(9): p. 8875-8881.

15. Yue, C. Y., et al., *IGFBP7 is associated to prognosis and could suppress cell survival in cholangiocarcinoma*. Artificial Cells Nanomedicine and Biotechnology, 2018. 46: p. 817-825.

16. Tian, X. Y., et al., *Low expression of insulin-like growth factor binding protein 7...*
associated with poor prognosis in human glioma. Journal of International Medical Research, 2014. 42(3): p. 651-658.

17.An, W., et al., Low Expression of IGFBP7 is Associated with Poor Outcome of Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2012. 19(12): p. 3971-3978.

18.Tomimaru, Y., et al., IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer, 2012. 130(2): p. 319-27.

19.Ruan, W. J., et al., IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biology & Therapy, 2007. 6(3): p. 354-359.

20.Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology, 2010. 25(9): p. 603-605.

21.Tierney, J. F., et al., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007. 8.

22.Dickersin, K. and J. A. Berlin, Metaanalysis - State-of-the-Science. Epidemiologic Reviews, 1992. 14: p. 154-176.

23.Higgins, J. P. T., et al., Measuring inconsistency in meta-analyses. British Medical Journal, 2003. 327(7414): p. 557-560.

24.Ferlay, J., et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359-86.

25.Torre, L. A., et al., Global Cancer Statistics, 2012. Ca-a Cancer Journal for Clinicians, 2015. 65(2): p. 87-108.

26.Furstenberger, G. and H. J. Senn, Insulin-like growth factors and cancer. Lancet Oncol, 2002. 3(5): p. 298-302.
27. Mohan, S. and D. J. Baylink, *IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms*. Journal of Endocrinology, 2002. 175(1): p. 19-31.

28. Heesch, S., et al., *Expression of IGFBP7 in acute leukemia is regulated by DNA methylation*. Cancer Science, 2011. 102(1): p. 253-259.

29. Lin, J., et al., *Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression*. Journal of Pathology, 2007. 212(1): p. 83-90.

30. Tomimaru, Y., et al., *Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells*. British Journal of Cancer, 2010. 102(10): p. 1483-1490.

31. Okamura, J., et al., *Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer*. Cancer Biology & Therapy, 2012. 13(3): p. 148-155.

32. Verhagen, H. J. M. P., et al., *IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival*. Cell Death & Disease, 2014. 5.

33. Pen, A., et al., *Insulin-like growth factor binding protein 7 exhibits tumor suppressive and vessel stabilization properties in U87MG and T98G glioblastoma cell lines*. Cancer Biology & Therapy, 2011. 12(7): p. 634-646.

34. Wajapeyee, N., et al., *Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines*. Molecular Cancer Therapeutics, 2009. 8(11): p. 3009-3014.

Tables
Due to technical limitations, Tables 1 - 3 are only available for download from the Supplementary Files section.

Figures

Figure 1

Flow diagram about the steps of literature selection.
| Study or Subgroup | log[Hazard Ratio] | SE     | Weight | Hazard Ratio IV, Fixed, 95% CI | Hazard Ratio IV, Fixed, 95% CI |
|-------------------|------------------|--------|--------|------------------------------|------------------------------|
| An.W /2012        | -0.3147          | 0.1634 | 10.9%  | 0.73 [0.53, 1.01]             |                              |
| Kim.J /2018       | -0.5978          | 0.1886 | 8.2%   | 0.55 [0.38, 0.80]             |                              |
| Liu.L /2014       | -0.5108          | 0.0633 | 72.7%  | 0.60 [0.53, 0.68]             |                              |
| Ruan.W.J /2007    | -0.9676          | 0.4104 | 1.7%   | 0.38 [0.17, 0.85]             |                              |
| Tian.X.Y /2014    | -0.4943          | 0.2282 | 5.6%   | 0.61 [0.39, 0.95]             |                              |
| Yue.C.Y /2018     | -1.8971          | 0.5605 | 0.9%   | 0.15 [0.05, 0.45]             |                              |
| Total (95% CI)    |                  |        | 100.0% | 0.60 [0.54, 0.66]             |                              |

Heterogeneity: Chi² = 9.00, df = 5 (P = 0.11); I² = 44%
Test for overall effect: Z = 9.57 (P < 0.00001)

**Figure 2**

Forest plots showing the relationship between IGFBP7 and OS (univariate).
Subgroup analysis of OS (univariate) according to IGFBP7 expression.
Figure 4

Forest plots showing the relationship between IGFBP7 and OS (multivariate).
Figure 5

Subgroup analysis of OS (multivariate) according to IGFBP7 expression.
Figure 6

Funnel plot to the evaluation of potential publication bias for OS with univariate analysis (A) and multivariate analysis (B).

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

Table 1.pdf
Table 3.pdf
Table 2.pdf